HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has entered into an agreement with Purdue Pharma L.P. to settle all outstanding patent litigation related to Impax’s generic version of the currently marketed, reformulated OxyContin®.
Help employers find you! Check out all the jobs and post your resume.
